December 1, 2008
By:Paul Radensky
A clear oversight framework for biomarker clinical laboratory tests used in personalized medicine is required.
 |
April 1, 2008
By:Peter N. Townshend, George Colindres
As more biotechs turn to convertible note financing instead of traditional venture capital, they need to be aware of investors' demands.
|
January 1, 2008
By:Sergio Garcia
Strategic alliances and partnering deals were a big biotech news story during 2006—with deal values setting an all time record of over $23 billion for the year. The strategic partnering trend continues during 2007 and in this column we present some frequently asked questions and answers about the merger and acquisition (M&A) activity in the life sciences sector.
|
| 
